What does SAB Biotherapeutics, Inc. do?

Jun 22 2025 07:12 PM IST
share
Share Via
SAB Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $16.54 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -183.22%.
Overview: SAB Biotherapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.

Financial Snapshot: Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025). Market cap: USD 16.54 Million (Micro Cap).

Key Metrics: P/E: NA (Loss Making), Industry P/E: NA, Dividend Yield: 0.00%, Debt Equity: -0.55, Return on Equity: -183.22%, Price to Book: 0.77.

Contact Details: Not available.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Is SAB Biotherapeutics, Inc. overvalued or undervalued?
Jun 25 2025 09:28 AM IST
share
Share Via
How big is SAB Biotherapeutics, Inc.?
Jun 22 2025 06:23 PM IST
share
Share Via